NO20062428L - Kombinasjoner for HCV-behandling - Google Patents
Kombinasjoner for HCV-behandlingInfo
- Publication number
- NO20062428L NO20062428L NO20062428A NO20062428A NO20062428L NO 20062428 L NO20062428 L NO 20062428L NO 20062428 A NO20062428 A NO 20062428A NO 20062428 A NO20062428 A NO 20062428A NO 20062428 L NO20062428 L NO 20062428L
- Authority
- NO
- Norway
- Prior art keywords
- hepatitis
- relates
- combinations
- virus
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Abstract
Foreliggende oppfinnelse vedrører ko-administasjon av en hepatitt C virus NS3/4A-proteaseinhibitor og en cytokrom P450-monooksygenaseinhibitor. Kombinasjonen virker ved å gripe irm i livssyklusen til hepatitt C-viruset og er derfor nyttig som en antiviral terapi. Som sådan kan kombinasjonen anvendes for å behandle eller forebygge hepatitt C-infeksjoner i pasienter, oppflrmelsen vedrører også sammensetninger omfattende kombinasjonen av inhibitorer. Oppflrmelsen vedrører også kit og farmasøytiske pakker omfattende en hepatitt C virus NS3/4Aproteaseinhibitor og en cytokrom P450-monooksygenaseinhibitor. Oppflrmelsen vedrører også fremgangsmåter for fremstilling av disse sammensetningene, kombinasjonene, kitene og pakkene.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51485303P | 2003-10-27 | 2003-10-27 | |
PCT/US2004/035549 WO2005042020A2 (en) | 2003-10-27 | 2004-10-27 | Combinations for hcv treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20062428L true NO20062428L (no) | 2006-05-29 |
Family
ID=34549356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20062428A NO20062428L (no) | 2003-10-27 | 2006-05-29 | Kombinasjoner for HCV-behandling |
Country Status (22)
Country | Link |
---|---|
US (3) | US20060003942A1 (no) |
EP (1) | EP1677827B1 (no) |
JP (1) | JP2007509950A (no) |
KR (1) | KR20060120162A (no) |
CN (1) | CN1893978A (no) |
AT (1) | ATE416789T1 (no) |
AU (1) | AU2004285503A1 (no) |
BR (1) | BRPI0415935A (no) |
CA (1) | CA2543696A1 (no) |
CY (1) | CY1110176T1 (no) |
DE (1) | DE602004018363D1 (no) |
DK (1) | DK1677827T3 (no) |
ES (1) | ES2319775T3 (no) |
IL (1) | IL175211A0 (no) |
MX (1) | MXPA06004723A (no) |
NO (1) | NO20062428L (no) |
PL (1) | PL1677827T3 (no) |
PT (1) | PT1677827E (no) |
RU (1) | RU2006118359A (no) |
SI (1) | SI1677827T1 (no) |
WO (1) | WO2005042020A2 (no) |
ZA (1) | ZA200603863B (no) |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA979327B (en) | 1996-10-18 | 1998-05-11 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease. |
SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US8377952B2 (en) * | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
UY28500A1 (es) | 2003-09-05 | 2005-04-29 | Vertex Pharma | Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc. |
BRPI0511900A (pt) * | 2004-06-08 | 2008-01-22 | Vertex Pharma | composições farmacêuticas |
US20070004635A1 (en) * | 2005-06-02 | 2007-01-04 | Schering Corporation | Method of treating interferon non-responders using HCV protease inhibitor |
CA2617679A1 (en) * | 2005-08-02 | 2007-02-08 | Steve Lyons | Inhibitors of serine proteases |
US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
US7964624B1 (en) * | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
AR055395A1 (es) * | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
AU2007217355B2 (en) | 2006-02-27 | 2012-06-21 | Vertex Pharmaceuticals Incorporated | Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same |
WO2007103934A2 (en) * | 2006-03-06 | 2007-09-13 | Abbott Laboratories | Compositions and methods of use of ritonavir for treating hcv |
AU2007227544B2 (en) | 2006-03-16 | 2012-11-01 | Vertex Pharmaceuticals Incorporated | Deuterated hepatitis C protease inhibitors |
JP2009530415A (ja) * | 2006-03-20 | 2009-08-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | 医薬組成物 |
US20070287664A1 (en) * | 2006-03-23 | 2007-12-13 | Schering Corporation | Combinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto |
UA100666C2 (uk) * | 2006-04-11 | 2013-01-25 | Новартіс Аг | Інгібітори нсv/віл та їх застосування |
WO2007149382A2 (en) * | 2006-06-19 | 2007-12-27 | The Cleveland Clinic Foundation | Therapeutic compositions and methods useful in treating hepatitis |
AP2985A (en) * | 2006-07-07 | 2014-09-30 | Gilead Sciences Inc | Modulators of pharmacokinetic properties of therapeutics |
EP2112925A4 (en) * | 2006-11-15 | 2013-01-09 | Abbott Lab | SOLID PHARMACEUTICAL DOSAGE FORMULATIONS |
JP2010519329A (ja) * | 2007-02-27 | 2010-06-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ阻害剤 |
TW200846343A (en) * | 2007-02-27 | 2008-12-01 | Vertex Pharma | Co-crystals and pharmaceutical compositions comprising the same |
AR067412A1 (es) * | 2007-07-06 | 2009-10-07 | Gilead Sciences Inc | Moduladores de propiedades farmaceuticas de productos terapeuticos |
US8492546B2 (en) * | 2007-08-30 | 2013-07-23 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
US20090082366A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched telaprevir |
AR068756A1 (es) * | 2007-10-10 | 2009-12-02 | Novartis Ag | Compuestos peptidicos, formulacion farmaceutica y sus usos como moduladores del virus de la hepatitis c |
US20100021540A1 (en) * | 2008-02-28 | 2010-01-28 | Abbott Laboratories | Tablets and Preparation Thereof |
EP2367824B1 (en) | 2008-12-23 | 2016-03-23 | AbbVie Inc. | Anti-viral derivatives of pyrimidine |
CA2740195A1 (en) | 2008-12-23 | 2010-07-01 | Abbott Laboratories | Anti-viral compounds |
US8314135B2 (en) * | 2009-02-09 | 2012-11-20 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole antivirals |
WO2010091413A1 (en) * | 2009-02-09 | 2010-08-12 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
US8188132B2 (en) | 2009-02-17 | 2012-05-29 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
US8242156B2 (en) * | 2009-02-17 | 2012-08-14 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
WO2010099432A2 (en) * | 2009-02-26 | 2010-09-02 | The Johns Hopkins University | Recognition of cyp2e1 epitopes |
US9765087B2 (en) | 2009-02-27 | 2017-09-19 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
US8101643B2 (en) * | 2009-02-27 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
US8673954B2 (en) | 2009-02-27 | 2014-03-18 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
RU2541571C2 (ru) * | 2009-04-15 | 2015-02-20 | Эббви Инк. | Противовирусные соединения |
WO2010122087A1 (en) * | 2009-04-25 | 2010-10-28 | F. Hoffmann-La Roche Ag | Methods for improving pharmacokinetics |
US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
CN102333772B (zh) * | 2009-06-11 | 2013-12-11 | 雅培制药有限公司 | 抗病毒化合物 |
US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
US8221737B2 (en) | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
WO2010148006A1 (en) * | 2009-06-16 | 2010-12-23 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
US8609648B2 (en) | 2009-07-02 | 2013-12-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8822700B2 (en) * | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8927709B2 (en) * | 2009-09-11 | 2015-01-06 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US9156818B2 (en) * | 2009-09-11 | 2015-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8703938B2 (en) * | 2009-09-11 | 2014-04-22 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8815928B2 (en) | 2009-09-11 | 2014-08-26 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8759332B2 (en) * | 2009-09-11 | 2014-06-24 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
EP2512480A4 (en) * | 2009-12-14 | 2013-05-15 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
MA34013B1 (fr) | 2010-01-25 | 2013-02-01 | Enanta Pharm Inc | Inhibiteurs du virus de l'hépatite c |
US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8623814B2 (en) * | 2010-02-23 | 2014-01-07 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
US8178531B2 (en) * | 2010-02-23 | 2012-05-15 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
JP2013521279A (ja) * | 2010-03-04 | 2013-06-10 | エナンタ ファーマシューティカルズ インコーポレイテッド | Hcv複製の阻害剤としての医薬併用剤 |
EP3290428B1 (en) | 2010-03-31 | 2021-10-13 | Gilead Pharmasset LLC | Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate |
US9127021B2 (en) | 2010-04-09 | 2015-09-08 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8778938B2 (en) | 2010-06-04 | 2014-07-15 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
EP2603080A4 (en) | 2010-08-12 | 2014-01-22 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
US9011833B2 (en) | 2010-10-08 | 2015-04-21 | Novartis Ag | Vitamin E formulations of sulfamide NS3 inhibitors |
EP2646453A1 (en) | 2010-11-30 | 2013-10-09 | Gilead Pharmasset LLC | Compounds |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
CN103687489A (zh) | 2011-05-18 | 2014-03-26 | 埃南塔制药公司 | 制备5-氮杂螺[2.4]庚烷-6-甲酸及其衍生物的方法 |
RU2013155713A (ru) | 2011-07-06 | 2015-08-20 | Профибрикс Бв | Составы для лечения ран |
DE202012013074U1 (de) | 2011-09-16 | 2014-10-29 | Gilead Pharmasset Lcc | Zusammensetzungen zur Behandlung von HCV |
KR101621181B1 (ko) * | 2011-10-10 | 2016-05-13 | 에프. 호프만-라 로슈 아게 | 항바이러스성 화합물 |
CN104436197A (zh) | 2011-10-21 | 2015-03-25 | 艾伯维公司 | 至少两种直接作用抗病毒剂的组合产品 |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
JP5677645B2 (ja) | 2011-10-21 | 2015-02-25 | アッヴィ・インコーポレイテッド | 少なくとも2種の直接作用型抗ウイルス剤、およびリバビリンを含むがインターフェロンを含まない、hcvを治療するための方法 |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
MX346239B (es) * | 2012-05-18 | 2017-03-13 | Replicor Inc | Composiciones y metodos de polipeptidos-complejo de quelato de oligonucleotido. |
WO2014004674A2 (en) * | 2012-06-27 | 2014-01-03 | Abbvie Inc. | Methods for treating hcv |
SG10201706949VA (en) | 2013-01-31 | 2017-09-28 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
TW202402283A (zh) * | 2015-06-30 | 2024-01-16 | 美商伊格集團國際股份有限公司 | 克立咪唑(clemizole)化合物於預防及治療肝癌之用途 |
EP3448392A4 (en) | 2016-04-28 | 2020-01-15 | Emory University | ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF |
WO2021009332A1 (en) * | 2019-07-18 | 2021-01-21 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2779653B1 (fr) * | 1998-06-11 | 2002-12-20 | Inst Nat Sante Rech Med | Utilisation de composes modulateurs du proteasome en therapie |
SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
SK288015B6 (sk) * | 2001-06-11 | 2012-11-05 | Virochem Pharma Inc. | Thiophene derivatives as antiviral agents for flavivirus infection |
TW200510391A (en) * | 2003-04-11 | 2005-03-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US7109172B2 (en) * | 2003-07-18 | 2006-09-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
UY28500A1 (es) * | 2003-09-05 | 2005-04-29 | Vertex Pharma | Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc. |
JP2007532474A (ja) * | 2003-10-10 | 2007-11-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ、特にhcvのns3−ns4aプロテアーゼの阻害剤 |
AR055395A1 (es) * | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
-
2004
- 2004-10-27 AU AU2004285503A patent/AU2004285503A1/en not_active Abandoned
- 2004-10-27 BR BRPI0415935-7A patent/BRPI0415935A/pt not_active IP Right Cessation
- 2004-10-27 ES ES04810032T patent/ES2319775T3/es active Active
- 2004-10-27 ZA ZA200603863A patent/ZA200603863B/en unknown
- 2004-10-27 CN CNA200480037505XA patent/CN1893978A/zh active Pending
- 2004-10-27 SI SI200431034T patent/SI1677827T1/sl unknown
- 2004-10-27 JP JP2006538195A patent/JP2007509950A/ja active Pending
- 2004-10-27 PT PT04810032T patent/PT1677827E/pt unknown
- 2004-10-27 RU RU2006118359/15A patent/RU2006118359A/ru not_active Application Discontinuation
- 2004-10-27 DE DE602004018363T patent/DE602004018363D1/de active Active
- 2004-10-27 WO PCT/US2004/035549 patent/WO2005042020A2/en active Application Filing
- 2004-10-27 KR KR1020067010372A patent/KR20060120162A/ko not_active Application Discontinuation
- 2004-10-27 CA CA002543696A patent/CA2543696A1/en not_active Abandoned
- 2004-10-27 EP EP04810032A patent/EP1677827B1/en active Active
- 2004-10-27 AT AT04810032T patent/ATE416789T1/de active
- 2004-10-27 US US10/974,538 patent/US20060003942A1/en not_active Abandoned
- 2004-10-27 DK DK04810032T patent/DK1677827T3/da active
- 2004-10-27 MX MXPA06004723A patent/MXPA06004723A/es active IP Right Grant
- 2004-10-27 PL PL04810032T patent/PL1677827T3/pl unknown
-
2006
- 2006-04-26 IL IL175211A patent/IL175211A0/en unknown
- 2006-05-29 NO NO20062428A patent/NO20062428L/no not_active Application Discontinuation
-
2009
- 2009-03-10 CY CY20091100274T patent/CY1110176T1/el unknown
- 2009-06-23 US US12/490,196 patent/US20100015090A1/en not_active Abandoned
-
2012
- 2012-01-23 US US13/355,638 patent/US20120114604A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20100015090A1 (en) | 2010-01-21 |
PT1677827E (pt) | 2009-03-13 |
WO2005042020A2 (en) | 2005-05-12 |
ES2319775T3 (es) | 2009-05-12 |
DK1677827T3 (da) | 2009-03-30 |
MXPA06004723A (es) | 2006-07-05 |
AU2004285503A1 (en) | 2005-05-12 |
ZA200603863B (en) | 2007-11-28 |
DE602004018363D1 (de) | 2009-01-22 |
JP2007509950A (ja) | 2007-04-19 |
CY1110176T1 (el) | 2015-01-14 |
CA2543696A1 (en) | 2005-05-12 |
US20060003942A1 (en) | 2006-01-05 |
CN1893978A (zh) | 2007-01-10 |
KR20060120162A (ko) | 2006-11-24 |
WO2005042020A3 (en) | 2005-06-23 |
SI1677827T1 (sl) | 2009-06-30 |
ATE416789T1 (de) | 2008-12-15 |
IL175211A0 (en) | 2006-09-05 |
PL1677827T3 (pl) | 2009-06-30 |
BRPI0415935A (pt) | 2007-01-02 |
RU2006118359A (ru) | 2007-12-10 |
EP1677827B1 (en) | 2008-12-10 |
EP1677827A2 (en) | 2006-07-12 |
US20120114604A1 (en) | 2012-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20062428L (no) | Kombinasjoner for HCV-behandling | |
SG159385A1 (en) | Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease | |
PT1268519E (pt) | Inibidores de serina protease, particularmente protease ns3 do virus da hepatite c | |
CL2004001161A1 (es) | Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c. | |
TW200518746A (en) | Novel inhibitors of hepatitis C virus NS3/NS4A serine protease | |
SG155967A1 (en) | Hcv ns3-ns4a protease inhibition | |
PL1987038T3 (pl) | Inhibitory HCV NS5B | |
MX2009009176A (es) | Inhibidores de serina-proteasas. | |
SG164376A1 (en) | Hcv ns3 protease inhibitors | |
HK1101402A1 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
TW200745120A (en) | Indolobenzazepine HCV NS5B inhibitors | |
ATE469155T1 (de) | Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer | |
UY28500A1 (es) | Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc. | |
UA90909C2 (en) | Hcv ns3 protease inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |